In Vitro Activities of Garenoxacin (BMS-284756) against Haemophilus influenzae Isolates with Different Fluoroquinolone Susceptibilities

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 11, 2003, Pages 3539-3541

  Pérez Vázquez, María ^a   Román, Federico ^a   Aracil, Belen ^a   Cantón, Rafael ^b   Campos, José ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFIXIME; CEFUROXIME; CIPROFLOXACIN; CLAVULANIC ACID; ERYTHROMYCIN; GARENOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; NALIDIXIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; DILUTION; GENE MUTATION; GYRA GENE; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PARC GENE; PRIORITY JOURNAL;

AMINO ACID SUBSTITUTION; ANTI-INFECTIVE AGENTS; DNA GYRASE; DNA TOPOISOMERASE IV; FLUOROQUINOLONES; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; QUINOLONES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 0242385491     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.11.3539-3541.2003     Document Type: Article

References (17)

1. Biedenbach, D. J., R. N. Jones, and M. A. Pfaller. 2001. Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States. Diagn. Microbiol. Infect. Dis. 39:245-250.
2. Bastida, T., M. Pérez-Vázquez, J. Campos, M. C. Cortés-Lletget, F. Román, F. Tubau, A. G. de la Campa, and C. Alonso-Tarrés. Therapeutic failure in a case of pneumonia due to levofloxacin-resistant Haemophilus influenzae. Emerg. Infect. Dis., in press.
3. Boswell, F. J., J. M. Andrews, and R. Wise. 2001. Comparison of the in vitro activities of BMS-284756 and four fluoroquinolones against Streptococcus pneumoniae. J. Antimicrob. Chemother. 48:446-447.
4. Campos, J., F. Román, M. Georgiou, C. García, R. Gómez-Lus, R. Cantón, H. Escobar, and F. Baquero. 1996. Long-term persistence of ciprofloxacin-resistant Haemophillus influenzae in patients with cystic fibrosis. J. Infect. Dis. 174:1345-1347.
5. Fung-Tomc, J. C., B. Minassian, B. Kolek, E. Huczko, L. Aleksunes, T. Stickle, T. Washo, E. Gradelski, L. Valera, and D. P. Bonner. 2000. Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756. Antimicrob. Agents Chemother. 44:3351-3356.
6. García-Rodriguez, J. A., F. Baquero, J. Garcia de Lomas, and L. Aguilar. 1999. Antimicrobial susceptibility of 1,422 H. influenzae isolates from respiratory tract infections in Spain. Results of 1-year (1996-97) multicenter surveillance study. Infection 27:265-267.
7. Georgiou, M., R. Muñoz, F. Roman, R. Cantón, R. Gómez-Lus, J. Campos, and A. De la Campa. 1996. Ciprofloxacin-resistant Haemophilus influenzae strains possess mutations in analogous positions of GyrA and ParC. Antimicrob. Agents Chemother. 40:1741-1744.
8. Hartman-Neumann, S., K. DenBleyker, L. A. Pelosi, L. E. Lawrence, J. F. Barrett, and T. J. Dougherty. 2001. Selection and genetic characterization of Streptococcus pneumoniae mutants resistant to Des-F(6) quinolone BMS-284756. Antimicrob. Agents Chemother. 45:2865-2870.
9. Hoellman, D. B., L. M. Kelley, M. A. Jacobs, and P. C. Appelbaum. 2001. Comparative antianaerobic activity of BMS-284756. Antimicrob. Agents Chemother. 45:589-592.
10. Ince, D., X. Zang, L. C. Silver, and D. C. Hooper. 2002. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone. Antimicrob. Agents Chemother. 46:3370-3380.
11. Lister, P. D. 2003. Impact of AUC/MIC ratios on the pharmacodynamics of the des-F(6) quinolone garenoxacin (BMS-284756) is similar to other fluoroquinolones. J. Antimicrob. Chemother. 51:199-202.
12. Nagai, A., M. Miyazaki, T. Morita, S. Furubo, K. Kizawa, H. Fukumoto, T. Sanzen, H. Hayakawa, and Y. Kawamura. 2002. Comparative articular toxicity of garenoxacin, a novel quinolone antimicrobial agent, in juvenile beagle dogs. J. Toxicol. Sci. 27:219-228.
13. National Committee for Clinical Laboratory Standards. 2001. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th ed. Approved standard M7-A6. National Committee for Clinical Laboratory Standards, Wayne, Pa.
14. National Committee for Clinical Laboratory Standards. 2001. Performance standards for antimicrobial susceptibility testing: eleventh informational supplement. NCCLS document M100-S11. National Committee for Clinical Laboratory Standards, Wayne, Pa.
15. Pankuch, G. A., K. Nagai, T. A. Davies, M. R. Jacobs, and P. C. Appelbaum. 2002. Antipneumococcal activity of BMS 284756 compared to those of six other agents. Antimicrob. Agents Chemother. 46:251-254.
16. Pérez-Vázquez, M., F. Román, M. C. Varela, R. Cantón, and J. Campos. 2003. Activities of thirteen quinolones by three susceptibility testing methods against a collection of Haemophilus influenzae isolates with different levels of susceptibility to ciprofloxacin: evidence for cross-resistance. J. Antimicrob. Chemother. 51:147-151.
17. Takahata, M., J. Mitsuyama, Y. Yamashiro, M. Yonezawa, H. Araki, Y. Todo, S. Minami, Y. Watanabe, and H. Narita. 1999. In vitro and in vivo antimicrobial activities of ME, a novel des-F(6)-quinolone. Antimicrob. Agents Chemother. 43:1077-1084.